Literature DB >> 150288

Two classes of site for ATP in the Ca2+-ATPase from human red cell membranes.

D E Richards, A F Rega, P J Garrahan.   

Abstract

(1) The response of the Ca2+-ATPase activity from human red cell membranes to ATP concentrations can be represented by the sum of two Michaelis-like curves: one with a Km of 2.5 micrometer and the other with a Km of 145 micrometer. (2) The maximum Ca2+-ATPase activity elicited by occupation of the site with lower Km represents about 10% of the activity attainable at non-limiting ATP concentrations. (3) 30--50% of the Ca2+-ATPase activity with lower Km remains in the absence of Mg2+ . Mg2+ increases V and the maximum effect of Ca2+, having no effect on the apparent affinities for ATP and Ca2+. (4) The large increase in Ca2+-ATPase activity which results from the occupation of the site with higher Km only takes place when Mg2+ is present. (5) Results are compatible with the idea that the Ca2+-ATPase from human red cell membranes has two classes of site for ATP binding, both of which are occupied when the enzyme catalyzes the hydrolysis of ATP at maximum rate. (6) The properties of the high affinity site suggest that this is the catalytic site of the Ca2+-ATPase. It is proposed that binding of ATP at the low affinity site regulates the turnover of the system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 150288     DOI: 10.1016/0005-2736(78)90313-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  20 in total

1.  Overexpression of the erythrocyte plasma membrane Ca2+ pump in COS-1 cells.

Authors:  H P Adamo; A K Verma; M A Sanders; R Heim; J L Salisbury; E D Wieben; J T Penniston
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

2.  Plasma membrane calcium pump activity is affected by the membrane protein concentration: evidence for the involvement of the actin cytoskeleton.

Authors:  Laura Vanagas; Rolando C Rossi; Ariel J Caride; Adelaida G Filoteo; Emanuel E Strehler; Juan Pablo F C Rossi
Journal:  Biochim Biophys Acta       Date:  2007-03-24

3.  Inhibition of the purified human red-cell Ca2+ pump by a monoclonal antibody.

Authors:  A J Caride; A Enyedi; J T Penniston
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

4.  Plasma membrane calcium ATPase activity is regulated by actin oligomers through direct interaction.

Authors:  Marianela G Dalghi; Marisa M Fernández; Mariela Ferreira-Gomes; Irene C Mangialavori; Emilio L Malchiodi; Emanuel E Strehler; Juan Pablo F C Rossi
Journal:  J Biol Chem       Date:  2013-06-26       Impact factor: 5.157

5.  The erythrocyte calcium pump is inhibited by non-enzymic glycation: studies in situ and with the purified enzyme.

Authors:  F L González Flecha; P R Castello; A J Caride; J J Gagliardino; J P Rossi
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

6.  Ca2+-stimulated ATPase: inactivation by Ca2+ and mechanism.

Authors:  C H Pedemonte; H F Balegno
Journal:  Mol Cell Biochem       Date:  1982-08-20       Impact factor: 3.396

7.  Hyperactivation of the human plasma membrane Ca2+ pump PMCA h4xb by mutation of Glu99 to Lys.

Authors:  Luciana R Mazzitelli; Hugo P Adamo
Journal:  J Biol Chem       Date:  2014-02-28       Impact factor: 5.157

8.  Erythrocyte-ghost Ca2+-stimulated Mg2+-dependent adenosine triphosphatase in Duchenne muscular dystrophy.

Authors:  M J Dunn; A H Burghes; V Dubowitz
Journal:  Biochem J       Date:  1982-03-01       Impact factor: 3.857

9.  Oxidant-induced inhibition of the plasma membrane Ca2+-ATPase in pancreatic acinar cells: role of the mitochondria.

Authors:  Erin M Baggaley; Austin C Elliott; Jason I E Bruce
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-11       Impact factor: 4.249

10.  Shadows of an absent partner: ATP hydrolysis and phosphoenzyme turnover of the Spf1 (sensitivity to Pichia farinosa killer toxin) P5-ATPase.

Authors:  Gerardo R Corradi; Felicitas de Tezanos Pinto; Luciana R Mazzitelli; Hugo P Adamo
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.